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ABSTRACT
Removal of central venous catheters (CVCs) from candidaemic patients is considered the reference
standard of care, although this practice is not always possible. The impact of prompt catheter removal
on outcome was investigated by analysing data from an active population-based surveillance study in
Barcelona, Spain. Patients with candidaemia and a CVC were identified between January 2002 and
December 2003. Cases with CVC removal within 2 days were classified as having early CVC removal.
Outcome, defined as in-hospital mortality 2–30 days after diagnosis of candidaemia, was determined
among hospitalised adults using univariate, Kaplan–Meier and multivariate logistic regression analysis.
Outpatients, paediatric patients and those who died or were discharged within 2 days were excluded.
The study identified 265 patients with candidaemia and a CVC. Median time from diagnosis of
candidaemia to catheter removal was 1 day (range 0–29 days). Overall, 172 patients met the criteria for
inclusion in the outcome study. Patients with early CVC removal differed significantly from those with
delayed CVC removal. According to univariate, Kaplan–Meier and multivariate analysis, the marker
most predictive of in-hospital mortality among candidaemic patients with CVCs was severity of illness.
These data suggest that timing of CVC removal may best be determined after carefully considering the
risks and benefits to individual patients.
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INTRODUCTION
Several studies have identified central venous
catheters (CVCs) as constituting an increased risk
for the development of candidaemia [1–3].
Although removal of CVCs from candidaemic
patients is considered the reference standard of
care [4,5], this practice is not always possible.
Previous studies have investigated the impact of
CVC removal on outcome, often defined as death,
and the persistence or recurrence of candidaemia
[1,4,6–14]. However, few data exist concerning the
most appropriate time for CVC removal, or the
sub-population of patients that would benefit
most from such an intervention. A recent
study, limited to patients suffering from cancer,
attempted to answer these questions, and
revealed an association between early CVC
Corresponding author and reprint requests: D. Rodriguez,
Infectious Diseases Division, Hospital Universitari Vall d’Heb-
ron, Pg. Vall d’Hebron 119-129, 08035 Barcelona, Spain
E-mail: dolorodriguez@vhebron.net
*Members of the Barcelona Candidemia Project Study
Group are listed in Table S1 (see Supplementary material).
 2007 The Authors
Journal Compilation  2007 European Society of Clinical Microbiology and Infectious Diseases
removal and improved outcome [14]. In order to
provide a better description of a population with
catheter-related candidaemia, and to understand
the effect of early CVC removal on these patients,
the present study analysed data from an active,
population-based surveillance study of candidae-
mia [13].
PATIENTS AND METHODS
Study population and definitions
Prospective population-based surveillance for candidaemia
was conducted in greater Barcelona (population 3.9 million)
between 1 January 2002 and 31 December 2003 [13]. Fourteen
major hospitals participated, ranging in size from 214 to 1295
beds. All candidaemic patients with a CVC in place for at
least 24 h at the time of candidaemia were included in this
analysis.
A candidaemia patient was defined as a resident of
Barcelona for whom a Candida sp. was isolated from blood.
Cases were defined as having primary candidaemia if there
was no apparent portal of entry or if the infection was
probably catheter-related. Secondary candidaemia cases were
defined as patients with infections that occurred after a
potential source of infection was identified. Catheter-related
candidaemia was recorded when a patient had primary
candidaemia and either (i) a catheter tip colonised with the
same Candida sp. that was isolated from the bloodstream, or (ii)
a quantitative blood culture sample obtained through the CVC
that showed a ‡five-fold greater colony count than a concur-
rent peripheral venous quantitative blood culture. Significant
colonisation of the catheter was defined by the isolation of
>15 CFU of a Candida sp. using the roll-plate semiquantitative
culture method [4,15].
Adult candidaemic patients with an APACHE II score ‡20
were defined as having a high severity of illness (SOI); adult
candidaemic patients with an APACHE II score <20 were
defined as having a low SOI.
To explore the effect of early catheter removal on outcome,
patients with early CVC removal were defined as those who
had the CVC removed on day 0 or 1 following the date of the
incident candidaemia. Outcome was defined as in-hospital
mortality measured at day 2–30 post-candidaemia onset.
Patients who died or were discharged before day 2 post-
candidaemia onset were excluded from the outcome analysis
because it was not possible to classify these cases into either
the early or delayed CVC removal categories. Inclusion of
patients who died before a decision was made regarding
removal could bias results towards showing an association
between non-removal and death.
Outpatients, paediatric patients and patients with multiple
CVCs were also excluded. Patients who developed candidae-
mia as outpatients would not have been subject to the outcome
measure of in-hospital mortality. Paediatric patients were
excluded because no SOI score was available. Patients with
multiple CVCs were omitted because many did not have all
CVCs removed on the same day, and therefore it was not
possible to define the exact date of removal. Patients with
multiple CVCs removed on the same day were also excluded,
as inclusion of these patients was felt to bias the study
population towards the group with CVCs removed.
Patients with early CVC removal were compared to those
with delayed CVC removal by comparing the time to death for
each of these groups using a Kaplan–Meier analysis. Kaplan–
Meier curves were compared using the log-rank test. In
addition, in-hospital mortality at 2–30 days post-candidaemia
onset was examined by comparing early removal to delayed
removal by univariate analysis. Stratified analysis was con-
ducted among subgroups of patients in intensive care units
(ICUs), those with preceding surgery, and those with malig-
nancies. Statistical analysis was performed using SPSS soft-
ware v.12.0 (SPSS Inc., Chicago, IL, USA) and SAS software
v.8.2 (SAS Institute, Cary, NC, USA). Categorical variables
were compared using chi-square analysis or Fisher’s exact test,
as appropriate. Median values were compared using the
Wilcoxon rank sum test. Variables significant at p <0.2
following univariate analysis, and other variables felt to
confound the outcome, were included in a multivariate model
that determined factors associated with in-hospital mortality at
days 2–30 post-candidaemia.
Microbiological methods
Detection of candidaemia and identification of isolates to the
species level were performed at the participating laborator-
ies. Isolates were sent to the Mycology Reference Laboratory,
National Center for Microbiology, Madrid, Spain for confir-
mation of species identity and antifungal susceptibility
testing. Catheter tips were cultured by means of the
semiquantitative roll-plate method described by Maki et al.
[15].
RESULTS
Cases with CVCs
During the study period, 265 cases of candidae-
mia were detected in patients with CVCs. The
majority of cases were episodes of primary can-
didaemia (n = 251, 95%); 145 (55%) of these had
no apparent portal of entry, and 106 (45%) were
probably catheter-related. Fourteen (5%)
cases were classified as secondary candidaemia
(Table 1).
At the time of candidaemia, 104 (40%) patients
were admitted to an ICU, 80 (32%) were in
medical wards, 50 (19%) were in surgical wards,
and 13 (5%) were in paediatric wards; 11 (4%)
were outpatients. Temporary non-tunnelled
CVCs were the most common type of CVC (167
patients; 63%); 36 (14%) were peripherally
inserted CVCs, 24 (9%) were infusion ports, and
nine (3%) were tunnelled CVCs. In addition, 29
(11%) patients had multiple CVCs.
Candida albicans was isolated most frequently
(48%), followed by Candida parapsilosis (26%),
Candida tropicalis (10%), Candida glabrata (7%),
Candida krusei (4%), and other Candida spp. (5%)
(Table 1).
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In-hospital mortality occurring on days 0–1
post-candidaemia onset occurred in 24 (9%)
patients, and post-candidaemia death in
2–30 days occurred in 82 (31%) patients (Fig. 1).
The median time from candidaemia onset to
catheter removal was 1 day (range 0–29 days).
Outcome study
Of 265 candidaemia patients with a CVC, 172
were included in the outcome study. Among the
excluded patients, 24 were excluded because of
death on days 0 or 1 post-candidaemia onset, and
one was discharged on these days. Additionally,
48 patients were paediatric patients, and 21
patients had multiple CVCs. Among the remain-
ing patients eligible for the outcome study, 37
(21%) CVCs were temporary CVCs inserted in
a jugular vein, 80 (46%) were inserted in a sub-
clavian vein, 21 (12%) were femoral, 17 (10%)
were peripherally inserted CVCs, five (3%) were
tunnelled CVCs, and 13 (8%) were infusion port
catheters.
The timing of CVC removal varied among
certain patient groups, and demonstrated that the
approach to CVC removal was heterogeneous.
ICU patients, patients receiving surgery in the
30-day period before infection, and those with a
high SOI were significantly more likely to have
their catheter removed early, whereas patients
with a malignancy or a non-temporary CVC were
significantly less likely to have their catheter
removed early (Table 2).
Overall, the time to death among cases with
early CVC removal, compared to delayed CVC
removal, did not differ significantly according to
Kaplan–Meier survival analysis (Fig. 2). Kaplan–
Meier curves were also created to examine
whether early removal was of benefit for patients
in ICUs, those with preceding surgery, or those
with a concomitant malignancy; however, no
difference in time to death was seen among these
groups (data not shown).
Following univariate analysis, cases with a high
SOI were associated significantly with in-hospital
mortality (relative risk (RR) 2.4, 95% CI 1.4–4.4),
Table 1. Characteristics of 265 patients with candidaemia
and a central venous catheter (CVC), stratified according to
type of candidaemia
Characteristic
Number (%)
Primary,
non-CVC-
related
(n = 145)
Primary,
CVC-related
(n = 106)
Secondary
(n = 14)
All cases
(n = 265)
Male gender 81 (56) 61 (57) 9 (64) 151 (57)
Neonate 11 (8) 8 (8) 4 (29) 23 (9)
Co-morbidities
Malignancy 58 (40) 35 (33) 7 (50) 100 (38)
Diabetes 28 (19) 23 (22) 3 (21) 54 (20)
Location in intensive
care unit
57 (39) 36 (34) 11 (79) 104 (40)
Surgery in previous
3 months
56 (39) 61 (58) 9 (64) 126 (48)
Previous antifungal agents 32 (22) 17 (16) 5 (36) 54 (20)
Previous corticosteroids 49 (34) 32 (30) 3 (21) 84 (32)
Parenteral
hyperalimentation
52 (36) 62 (58) 10 (71) 124 (47)
Candida species
identification
C. albicans 71 (49) 52 (49) 4 (29) 127 (48)
C. glabrata 13 (9) 2 (2) 4 (29) 19 (7)
C. tropicalis 19 (13) 7 (6) 1 (4) 27 (10)
C. parapsilosis 26 (18) 40 (38) 3 (21) 69 (26)
C. krusei 7 (5) 2 (2) 2 (14) 11 (4)
Other 9 (6) 3 (3) 0 (0) 12 (5)
Multiple CVCs 17 (12) 10 (9) 2 (14) 29 (11)
Non-temporary CVC 23 (16) 13 (12) 0 (0) 36 (14)
Early CVC 48 (33) 65 (61) 9 (64) 122 (46)
Treatment with
antifungal agents
118 (81) 101 (95) 11 (79) 230 (87)
Disseminated infection 6 (4) 4 (4) 3 (21) 13 (5)
High severity of
illness score
28 (19) 13 (12) 5 (36) 46 (17)
In-hospital death
0–1 days
post-candidaemia
21 (14) 2 (2) 1 (7) 24 (9)
In-hospital death
2–30 days
post-candidaemia
53 (37) 22 (21) 7 (50) 82 (31)
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Fig. 1. Days to death from onset of candidaemia for all
cases (n = 265).
Table 2. Characteristics associated with early or delayed
central venous catheter (CVC) removal among outcome
study patients (n = 172). Relative risk (RR) values >1
indicate variables associated with early CVC removal,
whereas values <1 indicate variables associated with
delayed CVC removal
Characteristic
Early,
n (%)
Non-early,
n (%) RR (95% CI) p value
ICU 32 (37) 12 (14) 1.7 (1.3–2.2) <0.01
High SOIa 20 (24) 7 (9) 1.6 (1.2–2.1) <0.01
Surgery 55 (64) 30 (35) 1.8 (1.3–2.5) <0.01
Malignancy 30 (34) 53 (62) 0.6 (0.4–0.8) <0.01
Non-temporary CVC 1 (1) 17 (20) 0.1 (0.01–0.7) <0.01
aData concerning SOI category were missing for seven patients.
ICU, intensive care unit; SOI, severity of illness category.
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whereas cases with C. parapsilosis isolates (RR 0.7,
95% CI 0.6–0.9) were associated with decreased
risk of in-hospital mortality (Table 3). Since the
approach to CVC removal in the present cohort
was significantly different for different exposure
groups, and these exposures were likely to affect
the measured outcome, these factors were con-
trolled in the multivariate model. After control-
ling for ICU admission, malignancy, preceding
surgery and the presence of a non-temporary
CVC, a high SOI score was associated independ-
ently in multivariate analysis with greater odds of
mortality (OR 6.1, 95% CI 2.4–15.6, p <0.01),
while isolation of C. parapsilosis was associated
with lower odds of mortality (OR 0.4,
95% CI 0.1–0.9, p 0.04) (Table 3). Early CVC
removal was not associated with significantly
decreased odds of in-hospital mortality.
Stratified univariate analysis was also per-
formed to evaluate whether early CVC removal
was of benefit to certain subgroups of patients.
Among ICU patients, those with preceding
surgery, those with malignancy and those with
CVC-related candidaemia, a high SOI score was
associated significantly with a higher risk of
in-hospital mortality; early CVC removal was
not associated with improved outcome (Table 4).
The subgroup of CVC-related candidaemia was
also analysed by multivariate analysis after
controlling for SOI, but no benefit was observed
(data not shown).
DISCUSSION
Although CVC removal is an important compo-
nent of treatment for candidaemia, particularly in
patients with an infected catheter, it is not clear
which patients benefit most from this practice, or
whether the timing of removal is critical to
improved outcome in all patients. In the present
study, data were analysed for a variety of adult
candidaemic patients identified through popula-
tion-based surveillance. The findings revealed
that the overall SOI remained the most important
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Fig. 2. Kaplan–Meier survival curve of the time to death
among candidaemic patients with early removal of central
venous catheter (CVC) (n = 87, dashed line), compared
with patients with delayed CVC removal (n = 85, solid
line).
Table 3. Characteristics associated with mortality during
the 2–30-day period post-candidaemia onset according to
univariate and multivariate analysis among adults with
central venous catheters (n = 173). Multivariate analysis
was conducted after controlling for high severity of illness,
location in an intensive care unit, concomitant malignancy,
preceding surgery, and the presence of a non-temporary
central venous catheter
Characteristic
Number (%)
RR (95% CI) p value
Death,
(n = 61)
Survival,
(n = 111)
High severity of illness categorya 19 (33) 8 (7) 2.4 (1.4–4.4) <0.01
C. parapsilosisa 7 (11) 31 (28) 0.7 (0.6–0.9) 0.01
Early removal 32 (52) 55 (50) 1.0 (0.8–1.3) NS
Antifungal treatment 54 (89) 105 (95) 0.7 (0.4–1.3) NS
aSignificant following multivariate analysis; odds ratio for high severity of illness
category = 6.1, 95% CI 2.4–15.6, p <0.01; odds ratio for C. parapsilosis isolate = 0.4
(0.1–0.9), p 0.04.
RR, relative risk.
Table 4. Characteristics associated with mortality during
the 2–30-day period post-candidaemia onset among selec-
ted subgroups of patients
Characteristic Death Survival RR (95% CI) p value
Among ICU patients (n = 44)
High SOI 12 (80) 7 (31) 2.3 (1.2–4.2) <0.01
Previous colonisation 13 (68) 10 (40) 1.6 (1.0–2.8) 0.08
Among surgical patients (n = 85)
High SOI 11 (46) 5 (9) 2.5 (1.2–5.3) <0.01
Among patients with
malignancy (n = 83)
High SOI 8 (28) 2 (4) 3.5 (1.0–12.1) <0.01
Infection with
Candida parapsilosis
3 (9) 14 (27) 0.7 (0.5–0.9) 0.09
Among patients with CVC-related
candidaemia (n = 75)
Previous immunosuppression 3 (18) 25 (43) 0.8 (0.6–1.0) 0.09
High SOI 5 (29) 4 (7) 1.8 (0.9–3.8) 0.02
RR, relative risk; ICU, intensive care unit; SOI, severity of illness score; CVC, central
venous catheter.
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predictor for in-hospital mortality, and it was not
possible to identify any subgroups of patients
who benefited significantly from early CVC
removal.
To date, there have been no randomised trials
in candidaemic patient populations that have
been conducted specifically to address the effects
of catheter removal vs. retention. In some stud-
ies, the role of catheter removal as a prognostic
factor of mortality has been evaluated using
observational data [1,6–14,16–22]. Many of these
studies have used varying patient populations
and approximations of SOI, which are factors
that should be considered when comparing the
results with those obtained in the present study.
Raad et al. [14] attempted to determine the
appropriate time for CVC removal, and the
sub-population of patients (patients with cath-
eter-related candidaemia, compared with those
with candidaemia from a non-catheter source)
that would benefit most from such an interven-
tion. Removal of CVCs <72 h after diagnosis of
candidaemia in patients with catheter-related
infection was found to result in an improved
response to antifungal therapy, defined as
resolution of all clinical manifestations of the
candidaemia and bloodstream sterilisation [14].
However, this previous study was limited to
patients with cancer (49% with haematological
malignancies and 51% with solid tumours), did
not adjust for SOI, and did not exclude patients
who died or were discharged before the defined
day of early catheter removal [14].
It is likely that catheter removal, particularly in
patients with infected catheters, is beneficial for
the treatment of candidaemia [5]. Unexpectedly,
the present study revealed that early catheter
removal was not beneficial, even in patients with
catheter candidaemia, and even after controlling
for SOI, which in multivariate analysis proved to
be the most predictive marker of in-hospital
mortality. Moreover, catheter removal is not
always possible without submitting patients to
greater risk, especially in clinical settings involv-
ing cancer or haemodialysis, because of difficulty
with venous access or co-morbidities such as
thrombocytopenia. Thus, in clinical practice, there
is a proportion of candidaemic cases that is
treated with catheter retention, despite long-
standing recommendations for immediate
removal of all CVCs [1,4,5,8,9,13,14,16–19]. The
present findings emphasise that each candidae-
mic patient must be assessed individually, and
that the benefits and risks of early catheter
removal must be considered carefully when
deciding on the management of such patients.
One of the limitations of using observational
data is the inability to control for all confounding
variables, including those that are known, e.g.,
SOI, and those that are unknown, e.g., the
tendency to remove CVCs earlier for some
subgroups of patients. Although some previous
studies have shown a benefit in removing CVCs
[1,7–14,16–21], other studies have shown that
patients whose CVC was retained had a signifi-
cantly higher SOI score [1,9,16]. The present
study attempted to understand some of these
confounding issues by investigating which fac-
tors in the cohort were associated with early or
delayed removal, and found that different
approaches to CVC removal were evident.
Patients in ICUs, and those with preceding
surgery, were more likely to have early removal
of a CVC, whereas patients with malignancy and
those with a non-temporary CVC, were not.
Interestingly, patients with a high SOI score were
more likely to be in the early CVC removal
group, possibly accounting for the absence of any
mortality benefit for early removal in univariate
analysis. However, even after these confounding
issues were controlled by including them in the
multivariate model, no benefit of early CVC
removal was detected. It was also impossible to
identify any subgroups of patients for whom
early CVC removal was beneficial. Intuitively, a
benefit was expected among patients with
CVC-related candidaemia. However, even after
controlling for SOI, early removal remained
non-significant.
Observational studies that attempt, either expli-
citly or implicitly, to assess the cause and effect
relationship between catheter removal and
outcome, e.g., mortality or improved response,
involve a difficult task. Factors that are associated
with outcome, e.g., underlying disease, location in
an ICU and SOI, can also be factors involved in a
clinician’s decision whether to remove the cath-
eter. These differences in background character-
istics between the treatment groups (early
removal vs. delayed removal) indicate possible
differences in baseline risk for the outcome, and
can thus lead to biased or even incorrect conclu-
sions. Appropriate methods and sample sizes,
adequate to address the heterogeneity with
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respect to baseline risk, are necessary in order to
explore the question of whether catheter removal
is beneficial for certain sub-populations of
patients.
In conclusion, it was not possible to demon-
strate that early removal of CVCs in patients with
candidaemia, as proposed by current guidelines
[4,5], was associated with improved outcome in
all patients. Patients are likely to benefit most
from a careful, individualised analysis of the risks
and benefits of the timing of catheter removal.
Further research should focus on determining the
subgroups that benefit most from this practice,
and should take into account the complicated
biases and confounders in these analyses.
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